Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study

被引：0
|
作者：
Guttman-Yassky, Emma [1 ]
Esfandiari, Ehsanollah [2 ]
Mano, Hirotaka [3 ]
Arai, Takahiro [4 ]
Kabashima, Kenji [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Kyowa Kirin, Marlow, England
[3] Kyowa Kirin, Tokyo, Japan
[4] Kyowa Kirin, Princeton, NJ USA
[5] Kyoto Univ, Grad Sch Med, Kyoto, Japan
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; moderate-to-severe; rocatinlimab; pruritis; OX40;
D O I：
10.1093/bjd/ljae266.053
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
679
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [2] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    [J]. Dermatology and Therapy, 2023, 13 : 595 - 608
  • [3] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao, Yan
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Jia, Yingmin
    Zhao, Guoqing
    Yan, Jinchun
    Chen, Bo
    [J]. CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
  • [4] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao Yan
    Zhang Jianzhong
    Yang Bin
    Li Jingyi
    Ding Yangfeng
    Wu Liming
    Zhang Litao
    Wang Jinyan
    Zhu Xiaohong
    Zhang Furen
    Tao Xiaohua
    Li Yumei
    Zhang Chunlei
    Li Linfeng
    Lu Jianyun
    Diao Qingchun
    Lu Qianjin
    Man Xiaoyong
    Li Fuqiu
    Xia Xiujuan
    Cheng Hao
    Jia Yingmin
    Zhao Guoqing
    Yan Jinchun
    Chen Bo
    [J]. 中华医学杂志(英文版), 2024, 137 (02)
  • [5] A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis
    Ehst, B.
    Silverberg, J.
    Lizzul, P.
    Luu, K.
    Papacharalambous, J.
    Raina, P.
    Randazzo, B.
    Sibley, C.
    Guttman-Yassky, E.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S347 - S347
  • [6] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Reich, Kristian
    Kabashima, Kenji
    Igawa, Ken
    Suzuki, Tetsuya
    Mano, Hirotaka
    Matsui, Takeshi
    Esfandiari, Ehsanollah
    Furue, Masutaka
    [J]. LANCET, 2023, 401 (10372): : 204 - 214
  • [7] Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
    Bieber, Thomas R. M.
    Thaci, Diamant
    Graham, Neil
    Pirozzi, Gianluca
    Teper, Ariel
    Ren, Haobo
    Radin, Allen
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB404 - AB404
  • [8] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [9] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [10] Tralokinumab significantly reduces Staphylococcus aureus colonization in adult patients with moderate-to-severe atopic dermatitis (AD): Results from a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
    Guttman-Yassky, E.
    Silverberg, J. I.
    Fensholdt, J.
    Lindegaard, K. K.
    Wollenberg, A.
    [J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 : 41 - 41
12345